Phase I Study of Lenalidomide in Patients With Acute Leukemia

Summary

Lenalidomide is a drug that alters the immune system and it may also be directly toxic to tumor. Therefore, in theory, it may reduce or prevent the growth of cancer cells or directly kill them. We will be studying how lenalidomide can be used to decrease bone marrow blast cells in preparation for a bone transplant.

Timeline

Start

2012-08

Primary completion

2017-05

Completion

2017-05

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of enrollment”

Drugs

Indications